HER2 Breast Cancer

Sara A. Hurvitz, MD, discusses some of the current important questions for the field of HER2-positive breast cancer now and highlights which of these unanswered questions she hopes are addressed soon.

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naive HER2-positive breast cancer.

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor, and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki showed promising antitumor activity in patients with chemotherapy-naïve, HER2-low, hormone receptor-positive metastatic breast cancer.

The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.

The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.

Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

Hatem Soliman, MD, discusses future directions for the HER2-positive breast cancer treatment landscape.

Johanna Kaufmann, PhD, discusses promising preclinical findings on first-in-class oncolytic viral therapy in breast cancer treatment.

In an interview, Funda Meric-Bernstam, MD, discussed the phase 2 DESTINY-PanTumor02 trial and the data on fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing cancers.

Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.

Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.

Hatem Soliman, MD, discusses some of the exciting research that is ongoing for patients with HER2-positive breast cancer.

The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, discusses the impact of trastuzumab deruxtecan, new developments, and unmet needs in the HER2-positive breast cancer space.

Hatem Soliman, MD, discusses second- and third-line strategies being used for the treatment of patients with HER2-positive metastatic breast cancer.

If approved, DB-1303 may provide a potential alternative to treatment with fam-trastuzumab deruxtecan-nxki for the treatment of patients with breast cancer.

According to Manali Bhave, MD, neratinib plus fulvestrant plus trastuzumab and should be considered as a therapeutic option with clinically meaningful benefit in patients with HER2-mutant metastatic breast cancer.

A review of fam-trastuzumab deruxtecan nxki shows how it has become a standard of care for patients with metastatic breast cancer that is HER2-positive.

Data from HER2CLIMB-02 will be presented at an upcoming medical meeting and the results will be shared with the FDA.

In an 8-year follow up analysis of patients on the ExteNET trial, researchers saw that overall survival was not significantly different to rates on placebo.

After success, preclinically and in a phase 1 dose-finding study, the phase 2 study of BDC-1001 has begun.

Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.

Health-related quality of life measures from the phase 3 DESTINY-Breast03 trial showed that patient-reported outcomes and time of hospitalization data favored trastuzumab deruxtecan despite having a longer duration of treatment than trastuzumab emtansine.

Funda Meric-Bernstam, MD, discusses fam-trastuzumab deruxtecan-nxki and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.